Advertisement

Topics

Companies Related to "Achillion Reports Preliminary Proof Concept With 4471 Treatment" [Most Relevant Company Matches] RSS

14:45 EDT 25th September 2018 | BioPortfolio

Here are the most relevant search results for "Achillion Reports Preliminary Proof Concept With 4471 Treatment" found in our extensive corporate database of over 50,000 company records.

Showing "Achillion Reports Preliminary Proof Concept With 4471 Treatment" Companies 1–25 of 3,800+

Extremely Relevant

Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections...


Relevant

Achillion Pharmaceuticals

Achillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis B and C viruses (HBV and HCV), HIV and herpes viruses.Product Candidate PortfolioThe Company’s broad drug developm...

Mucosis

Mucosis B.V. is a clinical-stage biotechnology company developing novel vaccines on its proprietary Mimopath® platform technology. The Mimopath® platform is being studied for various routes of administration including those that provide additional protection in the mucosa, the site where over 90% of pathogens enter the human body. Mucosis’s lead...


amcure GmbH

amcure GmbH is a spin-off from the Karlsruhe Institute of Technology established in 2011. The company develops peptide-based compounds for the treatment of highly metastatic forms of cancer. amcure’s most advanced development candidate has entered preclinical development. In vivo proof-of-concept studies indicate high efficacy against different types ...

Affinivax Inc.

Affinivax is advancing a next generation conjugate vaccine technology platform to enable the development of vaccines that provide the highest level of protection against challenging infectious diseases. Backed by an investment from the Bill & Melinda Gates Foundation and working with world experts in vaccine discovery and development, Affinivax is focused ...

Neuro3d

Neuro3d is a young pharmaceutical company aiming at development of new innovative treatments for central nervous system disorders. Neuro3d is a partially virtual company capable of discovering new active compounds and develop them quickly through Phase IIa. Neuro3d's present research focus is on depression, anxiety and schizophrenia. Neuro3d has produced innovative treatment concepts and managed t...

Novira Therapeutics, Inc.

Headquartered in Radnor, Pennsylvania, Novira www.noviratherapeutics.com is an antiviral drug discovery company that is focused on the discovery of novel, first-in-class therapeutics for the treatment of HBV and HIV, two global diseases in need of improved therapies. Novira’s advantage comes from using an innovative drug discovery and development paradigm ...

Phase 2 Discovery, Inc.

Phase 2 Discovery (P2D) is a pharmaceutical company focused on developing innovative drugs that fulfill unmet medical needs in the treatment of central nervous system (CNS) disorders such as insomnia, anxiety, depression, attention disorders and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).At P2D, we are using our understanding of the treatme...

Proof Eyewear

Proof was established in 2010 by three brothers in Boise, Idaho. They were inspired by their entrepreneur grandfather who started a wood sawmill and also by the outdoors around them. Proof creates one-of-a-kind eyewear from Eco-friendly materials such as sustainable woods that are sourced from managed forests, Eco acetate that is derived from the cotton pl...

Otic Pharma

FoamOtic is a novel foam-based drug delivery platform for the treatment of ear disorders. Otic Pharma completed proof-of-concept clinical trials with FoamOtic products for the treatment of acute otitis externa, demonstrating that its technology exerts its effect by a single daily administration as opposed to twice daily administration of the leading ear...

CancerDecisions®

If you or a loved one are dealing with cancer, The Moss Reports is an important ally in your corner. You can securely order a Moss Report right now by downloading it in electronic format from this Web site and having it delivered to your email box within minutes. Click here to order or to see a list of our 200+ Moss Reports, Dr. Moss's introductory letter, or a sample Table of Contents.Created by ...

BioAdvice

BioAdvice conducts in vivo preclinical studies from the screening phase till proof of concept studies.BioAdvice have extensive experience with: Biopharmaceuticals. Biomaterials. Devices. Conventional pharmaceuticals.

Living Proof, Inc.

Living Proof is a private beauty company based in Cambridge, MA. The company was co-founded in 2005 by Dr. Robert Langer, the David H. Koch Institute Professor at MIT, and Jon Flint, the co-founder of Polaris Partners. Living Proof invents and markets, worldwide, proprietary beauty products that are developed using advanced biotechnology and materials scie...

Axonyx

Axonyx is a biopharmaceutical company focused on the acquisition and development of proprietary products and technologies for the treatment and diagnosis of Alzheimer's Disease and other memory-related cognitive disorders including prion diseases such as Mad Cow Disease. After completion of a Phase II Proof of Concept clinical study in October of 2001 for Phenserine, Axonyx's lead product for Alzh...

Sunlight Research, LLC

Sunlight Research(TM) is the premier source for up-to-date Patent Data Analysis, Patent Claims Coverage Reports, Intellectual Property Market Research, Patent Analysis, Non-Practicing Entities Patent Reports and Interactive Freedom To Operate databases. Sunlight provides timely, in-depth and actionable patent analysis reports that are easily accessible and cost effective. Sample reports are avai...

Essentys AB

Essentys AB is an innovative biotech company developing therapeutics for the treatment and prevention of diseases in the elderly.The Company is currently focused on the development of its lead product ES 1 in osteoporosis, in which proof of concept has been obtained in clinical phase II studies. ES 1 constitutes a completely new approach to the treatment and prevention of osteoporosis. The data su...

SuperGen, Inc.

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com...

Poxel SAS

Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical companies. Poxel will further develop its portfolio by considering all opportunities corresponding to its core domain of competencies.

Living Proof

Living Proof was founded by a team of biotechnology researchers, expert stylists, and partners at Polaris Partners to solve the world’s toughest beauty problems. Today, our innovative products have received over 34 industry awards. Living Proof hair care products can be found nationwide at top salons Sephora, Ulta, Nordstrom, QVC and at Livingproof.com. ...

Washington G-2 Reports

An independent news and information service, specializing in diagnostic testing and related medical services, Washington G-2 Reports is the leading market research and publishing firm serving the clinical diagnostic laboratory market in the U.S. Washington G-2 Reports offers timely, accurate reporting and analysis to subscribers in all 50 states, Puerto Rico, Canada, Europe and Asia. In addition...

SuperGen Inc.

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com...

Catalyst Pharmaceutical Partners

Catalyst is a specialty pharmaceutical company of Coral Gables, Florida, that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction. Catalyst is developing vigabatrin (designated CPP-109 by Catalyst) for the treatment of addiction to cocaine, methamphetamine and other addictive substances. The National Institute on Drug Abuse has stated that f...

Boston Strategics Corporation (BSC)

BSC is an integrated drug R&D company with experience in developing, managing and optimizing global drug development programs from late discovery, through translational research, first-in-man and proof-of-concept studies. Its mission is to continuously improve patient health care by changing the drug R&D paradigm using “True” Open Innovationâ...

Affinivax, Inc.

Affinivax is advancing a next generation vaccine technology platform to enable the development of vaccines that provide the highest level of protection against challenging infectious diseases. Backed by an investment from the Bill & Melinda Gates Foundation, and working with world experts in vaccine discovery and development, Affinivax is focused on creati...

Avineuro Pharmaceuticals, Inc.

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.


More From BioPortfolio on "Achillion Reports Preliminary Proof Concept With 4471 Treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks